<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2906222289
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ROZAVI 10 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROSUVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        51.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>ROZAVI </strong>belongs to a group of medicines called Statins.</p><p>You have been prescribed ROZAVI because:</p><p>&bull; You have a high cholesterol level. This means you are at risk from a heart attack or stroke.<strong> ROZAVI</strong> is used in adults, adolescents and children 6 years or older to treat high cholesterol.</p><p>You have been advised to take a statin, because changing your diet and taking more exercise were not enough to correct your cholesterol levels. You should continue with your cholesterol-lowering diet</p><p>and exercise while you are taking ROZAVI .</p><p>Or</p><p>&bull; You have other factors that increase your risk of having a heart attack, stroke or related health problems.</p><p>Heart attack, stroke and other problems can be caused by a disease called atherosclerosis.</p><p>Atherosclerosis is due to build of fatty deposits in your arteries.</p><p><strong>Why is it important to keep taking ROZAVI?</strong></p><p>ROZAVI is used to correct the levels of fatty substances in the blood called lipids, the most common of which is cholesterol.</p><p>There are different types of cholesterol found in the blood &ndash; &lsquo;bad&rsquo; cholesterol (LDL-C) and &lsquo;good&rsquo; cholesterol (HDL-C).</p><p>&bull; ROZAVI can reduce the &lsquo;bad&rsquo; cholesterol and increase the &lsquo;good&rsquo; cholesterol.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp; It works by helping to block your body&rsquo;s production of &ldquo;bad&rdquo; cholesterol. It also improves your body&rsquo;s ability to remove it from your blood.</p><p>For most people, high cholesterol does not affect the way they feel because it does not produce any symptoms. However, if it is left untreated, fatty deposits can build up in the walls of your blood vessels causing them to narrow.</p><p>Sometimes, that narrowed blood vessels can get blocked which can cut off the blood supply to the heart or brain leading to a heart or a stroke. By lowering your cholesterol levels, you can reduce your risk of having a heart attack, a stroke or related health problems. You need to keep taking Rozavi , even if it has got your cholesterol to the right level, because it prevents your cholesterol levels from creeping up again and causing build up of fatty deposits. However, you should stop if your doctor tells you to do so, or you have become pregnant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take <strong>ROZAVI</strong>:</p><p>&bull; If you have ever had an allergic reaction to ROZAVI , or to any of its ingredients.</p><p>&bull; If you are pregnant or breast-feeding. If you become pregnant while Taking ROZAVI stop taking it immediately and tell your doctor. Women should avoid becoming pregnant while taking ROZAVI by using suitable contraception.</p><p>&bull; If you have liver disease.</p><p>&bull; If you have severe kidney problems.</p><p>&bull; If you have repeated or unexplained muscle aches or pains.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take a drug called ciclosporin (used, for example, after organ transplants)</p><p>&bull; If any of the above applies to you (or you are in doubt), please go back and see your doctor.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In addition, do not take Rosuvastatin 40 mg (the highest dose):</p><p>&bull; If you have moderate kidney problems (if in doubt, please ask your doctor).</p><p>&bull; If your thyroid gland is not working properly.</p><p>&bull; If you have had any repeated or unexplained muscle aches or pains, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines.</p><p>&bull; If you regularly drink large amounts of alcohol.</p><p>&bull; If you are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p>&bull; If you take other medicines called fibrates to lower your cholesterol.</p><p>&bull; If any of the above applies to you (or you are in doubt), please go back and see your doctor.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking Rozavi.</p><p>&bull; If you have problems with your kidneys.<br />&bull; If you have problems with your liver.<br />&bull; If you have had repeated or unexplained muscle aches or pains, a personal or<br />family history of muscle problems, or a previous history of muscle problems when<br />taking other cholesterol-lowering medicines. Tell your doctor immediately if you<br />have unexplained muscle aches or pains, especially if you feel unwell or have a fever.<br />Also, tell your doctor or pharmacist if you have a muscle weakness that is constant.<br />&bull; If you regularly drink large amounts of alcohol.<br />&bull; If your thyroid gland is not working properly.<br />&bull; If you take other medicines called fibrates to lower your cholesterol. Please read<br />this leaflet carefully, even if you have taken other medicines for high cholesterol<br />before.<br />&bull; If you take medicines used to treat the HIV infection e.g. ritonavir with lopinavir<br />and/or atazanavir, please see &ldquo;Other medicines and Rozavi&rdquo;.<br />&bull; If you are taking or have taken in the last 7 days a medicine called fusidic acid (a<br />medicine for bacterial infection), orally or by injection, please see &ldquo;Other medicines<br />and Rozavi&rdquo;.<br />&bull; If you are over 70 (as your doctor needs to choose the right start dose of Rozavi<br />to suit you)<br />&bull; If you have severe respiratory failure.<br />&bull; If you are of Asian origin &ndash; that is Japanese, Chinese, Filipino, Vietnamese, Korean<br />and Indian. Your doctor needs to choose the right start dose of Rozavi to suit you.</p><p>&bull; If you have or have had myasthenia (a disease with general muscle weakness including<br />in some cases muscles used when breathing), or ocular myasthenia (a disease causing<br />eye muscle weakness) as statins may sometimes aggravate the condition or lead to the<br />occurrence of myasthenia (see section 5).<br />&nbsp;</p><p><strong>&bull; If any of the above applies to you (or if you are not sure):</strong></p><p>&bull; Do not take RUSOVASTATIN 40 mg (the highest dose) and check with your doctor or pharmacist before you actually start taking any dose of ROZAVI.</p><p>In a small number of people, statins can affect the liver. This is identified by a simple test looks for increased levels of liver enzymes in the blood. For this reason, your doctor will usually carry out this blood test (liver function test) before and during treatment with ROZAVI .</p><p>&bull; While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.</p><p><strong>Children and adolescents</strong><br />&bull; If the patient is under 6 years old: ROZAVI should not be given to children younger<br />than 6 years.</p><p><strong>Other medicines and ROZAVI</strong></p><p>&bull; Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines</p><p>&bull; Tell your doctor if you are taking any of the following: ciclosporin (used for example, after organ transplants), warfarin or clopidogrel ( or any other drug used for thinning the blood), fibrates (such as gemfibrozil, fenofibrate) or any other medicine used to lower cholesterol ( such as ezetimibe) , indigestion remedies ( used to neutralize acid in your stomach), erythromycin (an antibiotic), fusidic acid (an antibiotic-please see warnings and precautions), an oral contraceptive (the pill), hormone replacement therapy or anti-viral medications such as (ritonavir with lopinavir and/or atazanavir or simeprevir (used to treat infections, including HIV or hepatitis C infection &ndash; please see Warnings and precautions). The effects of these medicines could be changed by ROZAVI or they could change the effects of ROZAVI</p><p>If you need to take oral fusidic acid to treat a bacterial infection you will need<br />to temporarily stop using this medicine. Your doctor will tell you when it is<br />safe to restart Rozavi. Taking Rozavi with fusidic acid may rarely lead to muscle<br />weakness, tenderness or pain (rhabdomyolysis). See more information regarding<br />rhabdomyolysis in Section 5.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>Patients taking statins should notify their health care professionals if they become<br />pregnant or suspect they are pregnant. Your health care professional will be able to<br />advise whether you should stop taking the medicine during pregnancy and whether you<br />may stop your statin temporarily while breastfeeding. Patients who are at high risk of<br />heart attack or stroke who require statins after giving birth should not breastfeed and<br />should use alternatives such as infant formula.</p><p><strong>Driving and using machines</strong></p><p>Most people can drive a car and operate machinery while using ROZAVI it will not affect their ability. However, some people feel dizzy during treatment with ROZAVI . If you feel dizzy, consult your doctor</p><p>before attempting to drive or use machines.</p><p><strong>ROZAVI contains lactose.</strong></p><p>If you have been told by your doctor that you have intolerance to some sugars (lactose or milk sugar), contact your doctor before taking ROZAVI.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>Usual doses in adults</strong></p><p>If you are taking <strong>ROZAVI</strong> for high cholesterol:</p><p><strong>Starting dose</strong></p><p>Your treatment with <strong>ROZAVI</strong> must start with the 5 mg or the 10 mg</p><p>dose, even if you have taken a higher dose of a different statin before.</p><p>The choice of your start dose will depend upon:&nbsp;</p><p>&bull; Your cholesterol level.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The level of risk you have of experiencing a heart attack or stroke</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Whether you have a factor that may make you more sensitive to possible side effects.</p><p>Please check with your doctor or pharmacist which start dose of <strong>ROZAVI</strong> will best suit you.</p><p>Your doctor may decide to give you the lowest dose (5 mg) if:</p><p>&bull; You are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p>&bull; You are over 70 years of age.</p><p>&bull; You have moderate kidney problems.</p><p>&bull; You are at risk of muscle aches and pains (myopathy).</p><p><strong>Increasing the dose and maximum daily dose</strong></p><p>Your doctor may decide to increase your dose. This is so that you are taking the amount of <strong>ROZAVI</strong> that is right for you. If you started with a 5 mg dose, your doctor may decide to double this to 10 mg, then 20</p><p>mg and then 40 mg if necessary. If you started on 10 mg, your doctor may decide to double this to 20 mg and then 40 mg if necessary.</p><p>There will be a gap of four weeks between every dose adjustment.</p><p>The maximum daily dose of <strong>ROZAVI</strong> is 40 mg. It is only for patients with high cholesterol levels and a high risk of heart attacks or stroke whose cholesterol levels are not lowered enough with 20 mg.</p><p>If you are taking <strong>ROZAVI</strong> to reduce your risk of having a heart attack, stroke or related health problems:</p><p>The recommended dose is 20 mg daily. However, your doctor may decide to use a lower dose if you have any of the factors mentioned above.</p><p><strong>Use in children and adolescents aged 6-17 years</strong></p><p>The dose range in children and adolescents aged 6 to 17 years is 5 to 20 mg once<br />daily. The usual start dose is 5 mg per day, and your doctor may gradually increase<br />your dose to find the right amount of ROZAVI for you. The maximum daily dose of<br />ROZAVI is 10 or 20 mg for children aged 6 to 17 years depending on your underlying<br />condition being treated. Take your dose once a day.<br />Rosuvastatin 40 mg tablet should not be used for children</p><p><strong>Taking your tablets</strong></p><p>Swallow each tablet whole with a drink of water.</p><p>Take ROZAVI once daily. You can take it at any time of the day with or without food. Try to take your tablet at the same time every day to help you to remember it.</p><p><strong>Regular cholesterol checks</strong></p><p>It is important to go back to your doctor for regular cholesterol checks, to make sure your cholesterol has reached and is staying at the correct level.</p><p>Your doctor may decide to increase your dose so that you are taking the amount of ROZAVI that is right for you.</p><p><strong>If you take more ROZAVI than you should</strong></p><p>Contact your doctor or nearest hospital for advice.</p><p>If you go into hospital or receive treatment for another condition, tell the medical staff that you&rsquo;re taking ROZAVI.</p><p><strong>If you forget to take ROZAVI </strong></p><p>Don&rsquo;t worry, just take your next scheduled dose at the correct time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking ROZAVI </strong></p><p>Talk to your doctor if you want to stop taking ROZAVI. Your cholesterol levels might increase again if you stop taking ROZAVI.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>It is important that you are aware of what these side effects may be.</p><p>They are usually mild and disappear after a short time.</p><p><strong>Stop taking ROZAVI and seek medical help immediately if you have any of the following allergic reactions:</strong></p><p>&bull; Difficulty in breathing, with or without swelling of the face, lips, tongue and/or throat</p><p>&bull; Swelling of the face, lips, tongue and/or throat, which may cause difficulty in swallowing</p><p>&bull; Severe itching of the skin (with raised lumps).</p><p>Also, stop taking ROZAVI and talk to your doctor immediately if you have any unusual aches or pains in your muscles which go on for longer than you might expect. Muscle symptoms are more common in</p><p>children and adolescents than in adults. As with other statins, a very small number of people have experienced unpleasant muscle effects and rarely these have gone on to become a potentially life threatening muscle damage known as rhabdomyolysis.</p><p><strong>Common possible side effects (these may affect between 1 in 10 and 1 in 100 patients):</strong></p><p>&bull; Headache</p><p>&bull; Stomach pain</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&bull; Feeling sick</p><p>&bull; Muscle pain</p><p>&bull; Feeling weak</p><p>&bull; Dizziness</p><p>&bull; Diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine.</p><p>&bull; An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your RUZOVASTATIN tablets (only RUZOVASTATIN 40 mg)</p><p><strong>Uncommon possible side effects (these may affect between 1 in 100 and 1 in 1,000 patients </strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, itching or other skin reactions</p><p>&bull; An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your ROZAVI&nbsp; tablets (only 5 mg, 10 mg and 20 mg).</p><p>Rare possible side effects (these may affect between 1 in 1,000 and 1 in 10,000 patients):</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reaction-signs include swelling of the face, lips,&nbsp; tongue and/or throat, difficulty in swallowing and breathing, a severe itching of the skin (with raised lumps). If you think you are having an allergic reaction, then stop taking ROZAVI and seek medical help immediately</p><p>&bull; Muscle damage in adults &ndash; as a precaution, stop taking ROZAVI and talk to your doctor immediately if you have any unusual aches or pains</p><p>in your muscles which go on for longer than expected</p><p>&bull; A severe stomach pain (inflamed pancreas)</p><p>&bull; Increase in liver enzymes in the blood</p><p><strong>Very rare possible side effects (these may affect less than 1 in 10,000 patients):</strong></p><p>&bull; Jaundice (yellowing of the skin and eyes)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis (an inflamed liver)</p><p>&bull; Traces of blood in your urine</p><p>&bull; Damage to the nerves of your legs and arms (such as numbness)</p><p>&bull; Joint pain</p><p>&bull; Memory loss</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast enlargement in men (gynaecomastia)&nbsp;</p><p>Side effects of unknown frequency may include:</p><p>&bull; Diarrhoea (loose stools)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens-johnson syndrome (serious blistering condition of the skin, mouth, eyes and genitals)</p><p>&bull; Cough</p><p>&bull; Shortness of breath</p><p>&bull; Oedema (swelling)</p><p>&bull; Sleep disturbances, including insomnia and nightmares</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual difficulties</p><p>&bull; Depression</p><p>&bull; Breathing problems, including persistent cough and/or shortness of</p><p>breath or fever</p><p>&bull; Tendon injury</p><p>&bull; Muscle weakness that is constant</p><p>&bull; Myasthenia gravis (a disease causing general muscle weakness including in some cases<br />muscles used when breathing).<br />&bull; Ocular myasthenia (a disease causing eye muscle weakness).<br />Talk to your doctor if you experience weakness in your arms or legs that worsens after<br />periods of activity, double vision or drooping of your eyelids, difficulty swallowing, or<br />shortness of breath.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Store below 30&deg;C.</p><p>Do not use ROZAVI. after the expiry date which is stated on the carton.</p><p>The expiry date refers to the last day of that month.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is rosuvastatin</p><p>&bull; ROZAVI 10 mg film-coated tablets contains 10.415 rosuvastatin calcium equivalent to 10</p><p>&bull; ROZAVI 20 mg film-coated tablets contains 20.83 rosuvastatin calcium equivalent to 20</p><p><strong>&bull; The other ingredients are:</strong></p><p>Crospovidone, Tribasic calcium phosphate, Lactose Fast Flow, Avicel PH</p><p>102, Magnesium stearate &amp; Opadry Pink</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                • ROZAVI 10 mg is Pink Round Shaped, biconcave from both sides, film coated tablets embossed with SJ 573 on one side.
• ROZAVI 20 mg is Pink Round Shaped, biconcave from both sides, film coated tablets embossed with SJ 575 on one side.
ROZAVI  20 ,10 mg.
Packs contain 28 film coated tablet

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals</p><p>Jeddah &ndash; Saudi Arabia</p><p><strong>To report any side effect </strong>(s)</p><p>&bull; Saudi Arabia<br />- The National Pharmacovigilance Centre (NPC):<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي هذا الدَّواء إلى مجموعة من الأدوية تُسمى الستاتينات.</p><p dir="RTL">لقد وُصِف لك روزافي لأنك:</p><p dir="RTL">&bull; تُعاني من ارتفاع مستوى الكوليسترول بالدَّم. يعني هذا أنك مُعرَّض لخطر الإصابة بنوبة قلبية أو سكتة دماغية. يُستَخدَم روزافي في البالغين والمراهقين والأطفال البالغين من العُمْر ٦ سنوات أو أكثر لعلاج ارتفاع الكوليسترول.</p><p dir="RTL">قد تم إسداء النَّصيحة لك لتناوُل الستاتينات؛ لأن تغيير نظامك الغذائي وممارسة المزيد من التَّمارين الرياضية لم يكن كافيًا لتصحيح مستويات الكوليسترول لديك. يجب أن تستمر في اتباع نظامك الغذائي الخافض للكوليسترول، وممارسة التَّمارين الرياضية أثناء تناوُلك روزافي</p><p dir="RTL">أو</p><p dir="RTL">&bull; لديك عوامل أخرى تُزيد من نسبة خطورة إصابتك بنوبة قلبية، أو سكتة دماغية، أو المشاكل الصحية ذات الصِّلة. قد تنجم النوبة القلبية، أو السكتة الدِّماغية، أو المشاكل الأخرى عن مرض يُدعى تصلُّب الشرايين.</p><p dir="RTL">تصلُّب الشرايين يكون نتيجة تراكم الترسُّبات الدهنية في الشرايين.</p><p dir="RTL">لماذا من المُهِم الاستمرار في تناوُل روزافي ؟</p><p dir="RTL">يُستَخدَم روزافي لتصحيح مستويات المواد الدُّهنية في الدَّم والتي تُدعى الدهون، الشكل الأكثر شيوعا منها هو الكوليسترول.</p><p dir="RTL">هناك أنواع مختلفة من الكوليسترول الموجود في الدَّم -الكوليسترول &quot;الضار&quot;&nbsp; (كوليسترول بروتين دهني منخفض الكثافة( والكوليسترول &quot;المفيد&quot;&nbsp; (كوليسترول البروتين الدُّهني مرتفع الكثافة(.</p><p dir="RTL">&bull; يُمكِن أن يُخفِّض روزافي مستويات الكوليسترول &quot;الضار&quot; ويُزيد مستويات الكوليسترول &quot;الجيد&quot;&nbsp; فهو يعمل عن طريق المساعدة في منع إنتاج جسمك للكوليسترول &quot;الضار&quot;. وهو أيضًا يُحسِّن قدرة جسمك على إزالته من دمك.</p><p dir="RTL">بالنِّسبة لمعظم الأشخاص، لا يُؤثر ارتفاع مستوى الكوليسترول على الطريقة التي يشعرون بها؛ لأنه لا يُؤدي إلى أي أعراض. مع ذلك، إذا تم تركه دون علاج، فقد تتراكم الترسُّبات الدُّهنية في جدران أوعيتك الدَّموية مما يُؤدي إلى تضيُّقها.</p><p dir="RTL">في بعض الأحيان، قد تتعرَّض هذه الأوعية الدَّموية المتضيِّقة للانسداد الأمر الذي قد يقطع وصول الدَّم إلى القلب أو المخ مما يُؤدي إلى الإصابة بنوبة قلبية أو سكتة دماغية. بخفض</p><p dir="RTL">مستويات الكوليسترول لديك، يُمكِنك خفض نسبة خطورة الإصابة بنوبة قلبية، أو سكتة دماغية، أو المشاكل الصحية ذات الصلة.</p><p dir="RTL">عليك الاستمرار في تناوُل روزافي، حتى إذا وصل الكوليسترول لديك إلى المستوى الصحيح؛ لأنه يقي من ارتفاع مستويات الكوليسترول مرة أخرى والتسبب في تراكم الترسُّبات الدُّهنية. مع ذلك، يجب عليك التَّوقف عن تناوُله إذا أخبرك طبيبك بذلك، أو إذا أصبحتِ حاملًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول روزافي في الحالات الآتية:</strong></p><p dir="RTL">&bull;في حال كان قد ظهر عليك تفاعلات حساسية في أي وقت مضى تجاه روزافي أو تجاه أي من مكوناته.</p><p dir="RTL">&bull;إذا كنتِ حاملًا أو مُرضعًا. إذا أصبحتِ حاملًا أثناء تناوُل روزافي، فتوقفي عن تناوُله فورًا وأخبري طبيبكِ. يجب على السيدات تجنُّب الحمل أثناء تناوُل روزافي عن طريق استخدام وسيلة منع حمل مناسبة.</p><p dir="RTL">&bull;إذا كنت تعاني من مشاكل بالكبد.</p><p dir="RTL">&bull;إذا كان لديك مشاكل شديدة في الكلى.</p><p dir="RTL">&bull;إذا أُصبت بأوجاع، أو آلام عضلية متكررة أو غير مُبررة.</p><p dir="RTL">&bull;إذا كنت تتناول سيكلوسبورين (يُستَخدَم، على سبيل المثال، بعد عمليات زرع الأعضاء). إذا انطبق عليك أيٌّ مما سبق (أو ساورك الشك)، فيُرجى الرجوع وزيارة الطبيب.</p><p dir="RTL">توخ حذرًا خاصًّا مع روزافي<strong>.</strong></p><p dir="RTL">وبالإضافة إلى ذلك ، لا تأخذ روزوفاستاتين ٤۰ ملج ) أعلى جرعة ( :</p><p dir="RTL">&bull;إذا كنت تعاني من مشاكل بالكلى.</p><p dir="RTL">&bull;إذا كنت تعاني من مشاكل بالكبد.</p><p dir="RTL">&bull;إذا أُصبت بأوجاع أو آلام عضلية متكررة أو غير مُبررة، كان لديك تاريخ مرضي شخصي أو عائلي من مشاكل العضلات، أو تاريخ سابق من مشاكل العضلات تناولت في حينه أدوية</p><p dir="RTL">أخرى خافضة للكوليسترول. أخبر طبيبك فورًا إذا كنت مصابًا بأوجاع أو آلام عضلية غير مُبررة، لا سيما إذا شعرت بتوعُّك أو حُمى. أخبر أيضًا طبيبك أو الصيدلي الخاص بك إذا كان لديك ضعف عضلي مستمر.</p><p dir="RTL">&bull;أخبر طبيبك إذا كنت تتناول كميات كبيرة من الكحوليات.</p><p dir="RTL">&bull;إذا كنت من أصول آسيويه) اليابانية والصينية والفلبينية والفيتنامية و الكورية والهندية (.</p><p dir="RTL">&bull;إذا كانت الغدة الدَّرقية لديك لا تعمل بشكل سليم.</p><p dir="RTL">&bull;إذا تناولت أدوية أخرى تُدعى الفيبرات لخفض الكوليسترول لديك. يُرجى قراءة هذه النَّشرة بعناية، حتى إذا تناولت أدوية أخرى لعلاج ارتفاع الكوليسترول من قبل.</p><p dir="RTL">&bull;إذا تناولت أدوية تُستَخدَم لعلاج عدوى فيروس نقص المناعة البشري على سبيل المثال:</p><p dir="RTL">ريتونافير مع لوبينافير و/أو أتازانافير، يُرجى الرجوع إلى &quot;تناوُل أدوية أخرى مع روزافي&quot;.</p><p dir="RTL">&bull;إذا تناولت خلال السبعة الايام الفائتة&nbsp;مضادات حيوية تحتوي على حمض الفيوسيديك،&nbsp; عن طريق افم أو الحقن يُرجى الرجوع إلى &quot;تناوُل أدوية أخرى مع روزافي&quot;.</p><p dir="RTL">&bull; إذا كان عمرك أكثر من 70 عامًا )حيث يحتاج طبيبك إلى اختيار جرعة البداية الصحيحة من روزافي لتناسبك(<br />&bull; إذا كان لديك فشل تنفسي حاد.<br />&bull; إذا كنت من أصول آسيويه )اليابانية والصينية والفلبينية والفيتنامية و الكورية والهندية( يحتاج طبيبك إلى<br />اختيار جرعة البداية الصحيحة من روزافي لتناسبك.</p><p dir="RTL">&bull;إذا كنـت تعـاني أو أصبـت بالوهـن العضـي (وهـو مـرض يصيـب ضعـف العضـات العـام و في بعـض الحـالات ايضـا<br />العضـات المسـتخدمة عنـد التنفـس.)<br />&bull; أو الوهـن العضـي العينـي (مـرض يسـبب ضعـف عضـات العـين) لأن السـتاتينات قـد يـؤدي في بعـض الأحيـان إلى<br />تفاقـم الحالـة أو يـؤدي إلى حـدوث الوهـن العضـي (انظـر القسـم .</p><p dir="RTL">إذا انطبق عليك أيٌّ مما سبق )أو ساورك الشك(:<br />&bull; لا تأخذ روزوفاستاتين 40 ملج ) أعى جرعة ( وتحقق مع طبيبك أو الصيدلي قبل البدء في اتخاذ أي جرعة<br />من روزافي<br />&bull; في عدد قليل من الأشخاص، يُكِن أن تُؤثر الستاتينات عى الكبد. يتم تحديد ذلك من خال اختبار بسيط<br />يبحث عن ارتفاع مستويات أنزيمات الكبد في الدَّم. لهذا السبب، سيُجري طبيبك عادةً اختبار الدَّم )اختبار<br />وظائف الكبد( قبل العاج بروزافي وخلاله.<br />&bull; إذا كنت تعاني من مرض السُّكَّرِيّ أو معرضًا للإصابة به، فسيقوم طبيبك بمتابعتك عن كثب أثناء الفرة التي<br />تتناول فيها هذا الدَّواء. من المحتمل أن تكون معرضًا لخطر الإصابة بمرض السُّكَّرِيّ إذا كنت تعاني من ارتفاع<br />مستويات السكر والدهون في الدَّم، أو زيادة في الوزن، وارتفاع ضغط الدَّم</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">&bull;إذا كان المريض تحت سن ٦ سنوات: يجب ألا يُعطى روزافي للأطفال الذين تقل أعمارهم عن ٦ أعوام.</p><p dir="RTL">&bull;إذا كان عُمرك يتجاوز ۷۰ عامًا) إذ يحتاج طبيبك إلى اختيار جرعة البدء الصحيحة من روزافي لتناسبك (.</p><p dir="RTL">&bull;إذا كان لديك فشل تنفسي شديد.</p><p dir="RTL">&bull;إذا كنت من أصل أسيوي - ياباني، صيني، فلبيني، فيتنامي، كوري، وهندي. يحتاج طبيبك إلى اختيار جرعة البدء الصحيحة من روزافي لتناسبك.</p><p dir="RTL">&bull;لا تأخذ روزوفاستاتين ٤۰ ملج (أعلى جرعة) وتحقق مع طبيبك أو الصيدلي قبل البدء فعليا اتخاذ أي جرعة من روزافي</p><p dir="RTL">&bull;في عدد قليل من الأشخاص، يُمكِن أن تُؤثر الستاتينات على الكبد. يتم تحديد ذلك من خلال اختبار بسيط يبحث عن ارتفاع مستويات إنزيمات الكبد في الدَّم. لهذا السبب، سيُجري طبيبك عادةً اختبار الدَّم )اختبار وظائف الكبد( قبل العلاج بروزافي وخلاله.</p><p dir="RTL">&bull;إذا كنت تعاني من مرض السُّكَّرِيّ أو معرضًا للإصابة به، فسيقوم طبيبك بمتابعتك عن كثب أثناء الفترة التي تتناول فيها هذا الدَّواء. من المحتمل أن تكون معرضًا لخطر الإصابة بمرض السُّكَّرِيّ إذا كنت تعاني من ارتفاع مستويات السكر والدهون في الدَّم، أو زيادة في الوزن، وارتفاع ضغط الدَّم.</p><p dir="RTL"><strong>الأدوية الآخرى و روزافي</strong></p><p dir="RTL">&bull;أخبر طبيبك أو الصيدلي إذا كنت تأخذ ، قد اخذت مؤخرا أو قد تأخذ أي أدوية أخرى.</p><p dir="RTL">&bull;أخبر طبيبك إذا كنت تأخذ أي من الأدويه التالية: سيكلوسبورين (الذي يستخدم على سبيل المثال ، بعد زرع الأعضاء) ، الوارفارين أو كلوبيدوجرل (أو أي نوع من الأدوية الأخرى المستخدمة لمنع تجلط الدم) ، الفايبرات (مثل جمفبروزيل ، فينوفايبرات) أو أي أدوية أخرى تستخدم لخفض الكولسترول (مثل إزتيميب) ، و علاجات عسر الهضم (التي تستخدم لتحييد الحمض الموجود في المعدة ) ،ريجورافينيب )يستخدم لعاج السرطان(،</p><p dir="RTL">الاريثروميسين (مضاد حيوي)، وحمض الفوسيديك (مضاد حيوي - يرجى الاطلاع على التحذيرات والاحتياطات) ، وسائل منع الحمل عن طريق الفم حبوب منع الحمل) ، العلاج بالهرمونات أو الأدوية المضادة للفيروسات مثل ريتونافير مع وبينافير و / أو اتازنفير أو سيميبرفير&nbsp; أوبيتاسافير، باريتابيريف ر، داسابوفير، فيلباتاسفير، غرازوبيف ر،<br />الباسفير، غليسابيرفير أو بيبرينتاسفير (التي تستخدم لعلاج العدوي ، بما في ذلك فيروس نقص يرجى الاطلاع على التحذيرات والاحتياطات) . ويمكن - C المناعة البشرية أو التهاب الكبد تغيير آثار هذه الأدوية من قبل روزافي أو أنها يمكن أن تغير من آثار روزافي</p><p dir="RTL">إذا كنت بحاجة إلى تناول حمض الفوسيديك عن طريق الفم لعاج عدوى بكتيرية، فستحتاج إلى التوقف مؤقتًا<br />عن استخدام هذا الدواء. سيخبرك طبيبك عندما يكون من الآمن إعادة تناول روزافي. أخذ روزافي مع حامض<br />الفوسيديك نادرًا ما يؤدي إلى ضعف العضات، إياَم أو الألم )انحال الربيدات(. انظر المزيد من المعلومات<br />. حول انحال الربيدات في القسم5</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية</strong></p><p dir="RTL">يجــب عــى المــرضى الذيــن يتناولــون أدويــة الســتاتين إبــاغ أخصــائي الرعايــة الصحيــة عنــد الحمــل أو الاشــتباه في<br />الحمـل. وذلـك ليتمكـن أخصـائي الرعايـة الصحيـة مـن تقديـم التوصيـات الازمـة بخصـوص اسـتخدام السـتاتين أثنـاء<br />الحمـل والرضاعـة يتوجـب عـى المـرضى المعرضـين لخطـر الإصابـة بنوبـة قلبيـة أو سـكتة دماغيـة والذيـن يحتاجـون إلى<br />أدويـة السـتاتين بعـد الـولادة عـدم الرضاعـة واسـتخدام البدائـل مثـل حليـب الأطفـال</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يُمكِن لغالبية الأشخاص قيادة السيارة وتشغيل الآلات أثناء استخدام روزافي - لن يُؤثر على قدرتهم. مع ذلك، يشعر بعض الأشخاص بالدوخة أثناء العلاج بروزافي<strong>. </strong>إذا شعرت بدوخة، استشر طبيبك قبل محاولة القيادة أو استخدام الآلات.</p><p dir="RTL">يحتوي روزافي على سكر اللاكتوز.</p><p dir="RTL">إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات )اللاكتوز أو سكر اللبن(، فاتصل به قبل تناوُل روزافي <strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناوَل دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مراجعة الطبيب أو الصيدلي إذا لم</p><p dir="RTL">تكن متأكدًا من كيفية التَّناول.</p><p dir="RTL">الجرعات المُعتادة في البالغين</p><p dir="RTL">إذا كنت تتناول روزافي لعلاج ارتفاع الكوليسترول:</p><p dir="RTL">جرعة البدء</p><p dir="RTL">يجب بدء العلاج بروزافي بجرعة ٥ ملج أو ۱۰ ملج، حتى إذا تناولت جرعة أكبر من أحد الستاتينات المختلفة من قبل. سيعتمد اختيار جرعة البدء الخاصَّة بك على:</p><p dir="RTL">&bull;مستوى الكوليسترول لديك.</p><p dir="RTL">&bull;مستوى خطورة تعرُّضك للإصابة بنوبة قلبية، أو سكتة دماغية.</p><p dir="RTL">&bull;إذا كان لديك أحد العوامل التي قد تجعلك أكثر حساسية للآثار الجانبية المُحتَمَلة.</p><p dir="RTL">يُرجى مراجعة طبيبك أو الصيدلي الخاص بك؛ لمعرفة أي جرعة بدء من روزافي تناسبك بشكل أفضل.</p><p dir="RTL">قد يقرر طبيبك إعطاءك الجرعة الأقل ( ٥ ملج) في الحالات الآتية:</p><p dir="RTL">&bull;إذا كنت من أصل أسيوي) ياباني، صيني، فلبيني، فيتنامي، كوري، وهندي (</p><p dir="RTL">&bull; إذا كنت أكبر من ۷۰ عامًا.</p><p dir="RTL">&bull; إذا كنت مُصابًا بمشاكل معتدلة في الكُلى.</p><p dir="RTL">&bull; إذا كنت معرضًا لخطر الإصابة بأوجاع وآلام العضلات) اعتلال عضلي (.</p><p dir="RTL">زيادة الجرعة والجرعة اليومية القصوى</p><p dir="RTL">قد يقرر طبيبك زيادة جرعتك حتى تتناول الكمية التي تناسبك من روزافي. إذا بدأت بجرعة 5 ملج، فقد يقرر طبيبك مضاعفة الجرعة إلى ۱۰ ملج، ثم ۲۰ ملج، ثم ٤۰ ملج إذا لزم الأمر.</p><p dir="RTL">إذا بدأت بجرعة ۱۰ ملج، فقد يقرر طبيبك مضاعفة الجرعة إلى ۲۰ ملج، ثم ٤۰ ملج إذا لزم الأمر. سيكون هناك فاصل زمني أربعة أسابيع بين كل تعديل للجرعة.</p><p dir="RTL">أقصى جرعة يومية من روزافي هي ٤۰ ملج. ذلك فقط للمرضى الذين لديهم مستويات الكوليسترول مرتفعة، ولديهم نسبة خطورة مرتفعة للإصابة بنوبات قلبية أو سكتة دماغية، والذين لم تنخفض لديهم مستويات الكوليسترول بشكل كافٍ مع الجرعة التي قدرها ۲۰ ملج. إذا كنت تتناول روزافي لخفض نسبة خطورة إصابتك بنوبة قلبية، أو سكتة دماغية، أو المشاكل الصحية ذات الصلة:</p><p dir="RTL">الجرعة الموصى بها هي ۲۰ ملج يوميًّا. مع ذلك، قد يقرر طبيبك استخدام جرعة أقل إذا كان لديك أي من العوامل المذكورة أعلاه.</p><p dir="RTL">الاستخدام في الأطفال والمراهقين من عمر ٦ إلى ۱۷ عامًا</p><p dir="RTL">تراوح الجرعة عند الأطفال والمراهق ن الذين تراوح أعمارهم ب ن 6 سنوات و 17 سنة من 5 إلى 20 ملج مرة<br />واحدة يوميًا. جرعة البدء المعتادة هي 5 ملج يوميًا ، وقد يزيد طبيبك الجرعة تدريجياً للعثور عى الجرعه<br />المناسبة لك من روزافي . الحد الأقى للجرعة اليومية من روزافي هو 10 أو 20 ملج للأطفال الذين تراوح<br />أعمارهم ب ن 6 إلى 17 سنة حسب الحالة التي يتم علاجها. تناول الجرعة مرة واحدة في اليوم.<br />لا ينبغي أن يستخدم الأطفال روزوفاستاتين 40 ملج</p><p dir="RTL">طريقة تناوُل القرص</p><p dir="RTL">ابلع القرص كاملًا مع بعض الماء.</p><p dir="RTL">تناول روزافي مرة واحدة يوميًّا. يمكنك تناوُله مع الطعام أو بدونه.</p><p dir="RTL">حاول أن تأخذ القرص في نفس الوقت كل يوم لمساعدتك على تذكرها.</p><p dir="RTL">فحوصات الكوليسترول المنتظمة</p><p dir="RTL">من المُهِم الرجوع إلى طبيبك للخضوع لفحوصات الكوليسترول بصفة منتظمة؛ للتَّأكد من أن الكوليسترول لديك قد وصل إلى أو لا يزال عند المستوى الصحيح.</p><p dir="RTL">قد يقرر طبيبك زيادة جرعتك بحيث تتناول الكمية المناسبة لك من روزافي.</p><p dir="RTL">إذا تناولت كمية أكثر مما يجب من روزافي</p><p dir="RTL">اتصل بطبيبك أو أقرب مستشفى لتلقي المشورة.</p><p dir="RTL">إذا ذهبت إلى المستشفى أو تلقيت علاجًا لحالة أخرى، فأخبر الطاقم الطبي أنك تتناول روزافي.</p><p dir="RTL">إذا نسيت تناوُل روزافي:</p><p dir="RTL">لا تقلق، فقط تناول جرعتك التَّالية في الموعد المُقرر لها. لا تتناول جرعة مضاعفة لتعويض جرعة نسيتها .</p><p dir="RTL">إذا توقفت عن تناوُل روزافي:</p><p dir="RTL">تحدَّث إلى طبيبك إذا أردت التَّوقف عن تناوُل روزافي. قد ترتفع مستويات الكوليسترول لديك مرة أخرى إذا توقفت عن تناوُل روزافي.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواءأعراضا جانبية، على الرَّغم من عدم حدوثها لدى الجميع. من المُهِم أن تُدرِك ماهية هذه الآثار الجانبية. تكون عادةً خفيفة إلى معتدلة وتختفي بعد فترة قصيرة.</p><p dir="RTL">توقف عن تناوُل روزافي واطلب المساعدة الطبية فورًا إذا أصُِبت بأي من تفاعلات الحساسية التاَّلية:</p><p dir="RTL">&bull; إذا حدث لديك صعوبة في التَّنفس مع تورم الوجه، الشفاه، اللسان و/أو الحلق أو بدون ذلك.</p><p dir="RTL">&bull; إذا حدث لديك تورم الوجه، الشفاه، اللسان و/أو الحلق الذي قد يُؤدي إلى صعوبة في البلع.</p><p dir="RTL">&bull; إذا حدث لديك حكَّة شديدة للجلد) مع كتل بارزة (.</p><p dir="RTL">توقف أيضًا عن تناوُل روزافي وتحدَّث إلى طبيبك فورًا إذا أصبت بأي أوجاع أو آلام غير مُعتادة في عضلاتك، والتي تستمر لفترة أطول مما قد تتوقع. تُعَد الأعراض العضلية أشيع في الأطفال والمراهقين عن البالغين. كما هو الحال مع الستاتينات الأخرى، تعرَّض عدد قليل للغاية من الأشخاص إلى أعراض عضلية مُضَايِقة ونادرًا ماتستمر هذه الآثار؛ لتصبح تلفًا عضليًّا قد يكون مُهَددًا للحياة يُعرَف باسم انحلال الربيدات.</p><p dir="RTL">) الآثار الجانبية المحتملة الأكثر شيوعًا (تُؤثر على ما بين ۱ مريض من ۱۰ و ۱ مريض من ۱۰۰</p><p dir="RTL">&bull; صداع.</p><p dir="RTL">&bull; ألم بالمعدة.</p><p dir="RTL">&bull; إمساك.</p><p dir="RTL">&bull; الشعور بالإعياء.</p><p dir="RTL">&bull; ألم في العضلات.</p><p dir="RTL">&bull; شعور بالضعف.</p><p dir="RTL">&bull; دوخة.</p><p dir="RTL">&bull; مرض السُّكَّرِيّ. من المرجح حدوث ذلك إذا كنت تعاني من ارتفاع مستويات السكر والدهون في الدَّم، أو زيادة الوزن وتعاني من ارتفاع ضغط الدَّم. سيقوم طبيبك بمتابعتك أثناء الفترة التي تتناول فيها هذا الدَّواء.</p><p dir="RTL">&bull;زيادة في كمية البروتين في البول - وهذا عادة ما يعود إلى وضعها الطبيعي من تلقاء نفسها دون الحاجة إلى التوقف عن تناول أقراص روزوفاستاتين الخاص بك) فقط روزوفاستاتين ٤۰ ملغ (</p><p dir="RTL">الآثار الجانبية المُحتَمَلة غير الشائعة )قد تؤُثر على ما بين مريض واحد من كل ۱۰۰ ، ومريض واحد من كل ۱۰۰۰ مريض):</p><p dir="RTL">&bull; طفح جلدي، أو حكة، أو تفاعلات جلدية أخرى.</p><p dir="RTL">&bull; ارتفاع في كمية البروتين في البول - يعود هذا عادةً إلى وضعه الطبيعي من تلقاء نفسه دون الحاجة إلى التَّوقف عن تناوُل روزافي أقراص الخاص بك) فقط روزافي ٥ ملج، و ۱۰ ملج، و ۲۰ ملج(.</p><p dir="RTL">الآثار الجانبية المُحتَمَلة النَّادرة (قد تؤُثر على ما بين مريض واحد من كل ۱۰۰۰ ، ومريض واحد من كل ۱۰۰۰۰ مريض):</p><p dir="RTL">&bull; تفاعلات حساسية شديدة - علامات تشمل: تورُّم الوجه، الشفتين، اللسان و/أو الحَلْق، صعوبة في البلع والتَّنفس، حكة شديدة بالجلد (مع كتل مرتفعة). إذا كنت تعتقد أنك مُصاب بتفاعل حساسية، فتوقف عن تناوُل روزافي، واطلب المساعدة الطبية فورًا.</p><p dir="RTL">&bull; التَّلف العضلي في البالغين - كإجراء احترازي، توقف أيضًا عن تناوُل روزافي، وتحدَّث إلى طبيبك فورًا إذا أصبت بأي أوجاع أو آلام غير مُعتادة في عضلاتك، والتي تستمر لفترة أطول مما تتوقع.</p><p dir="RTL">&bull; ألم شديد بالمعدة) التهاب البنكرياس (.</p><p dir="RTL">&bull; ارتفاع بإنزيمات الكبد في الدَّم.</p><p dir="RTL">الآثار الجانبية المُحتَمَلة النادرة جدًّا (قد تؤُثر هذه الآثار الجانبية على أقل من مريض واحد من كل 10000 مريض:</p><p dir="RTL">&bull; يرقان (اصفرار الجلد والعينين (</p><p dir="RTL">&bull; التهاب الكبد.</p><p dir="RTL">&bull; آثار دم في البول.</p><p dir="RTL">&bull; تلف بأعصاب الساقين والذراعين) مثل التَّنميل (</p><p dir="RTL">&bull; آلام المفاصل.</p><p dir="RTL">&bull; فقدان الذاكرة.</p><p dir="RTL">&bull; تضخم الثَّدي لدى الرجال (التثدي).</p><p dir="RTL">قد تشمل الآثار الجانبية غير المعروف معدَّل تكرارها ما يلي:</p><p dir="RTL">&bull; إسهال) براز رخو (</p><p dir="RTL">&bull; متلازمة ستيفنز جونسون) حالة خطيرة من ظهور النفطات على الجلد، والفم، والعينين، والأعضاء التناسلية (.</p><p dir="RTL">&bull; سعال.</p><p dir="RTL">&bull; ضيق بالتَّنفس.</p><p dir="RTL">&bull; وذمة) توَرُّمًا (.</p><p dir="RTL">&bull; اضطرابات النَّوم، بما في ذلك الأرق والكوابيس.</p><p dir="RTL">&bull; صعوبات جنسية.</p><p dir="RTL">&bull; الاكتئاب.</p><p dir="RTL">&bull; التهاب بالرئتين يُسبب مشاكل في التَّنفس تتضمن سعال دائم، و/أو ضيق التَّنفس، أو حمى.</p><p dir="RTL">&bull; إصابة بالوتر.</p><p dir="RTL">&bull; ضعف العضلات المستمر.</p><p dir="RTL">&bull;الوهــن العضــي الوبيــل (مــرض يســبب ضعــف عــام للعضــات و في بعــض الحــالات ايضــا العضــات المســتخدمة<br />عنــد التنفــس.)<br />&bull; الوهن العضي العيني الوبيل (مرض يسبب ضعف عضات العين.)<br />ً تحـدث إلى طبيبـك إذا كنـت تعـاني مـن ضعـف في ذراعيـك أو سـاقيك يـزداد سـوءا بعـد فـترات النشـاط أو الرؤيـة<br />المزدوجـة أو تـدلي الجفـون أو صعوبـة البلـع أو ضيـق التنفـس</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيدًا عن مُتناوَل الأطفال.</p><p dir="RTL">يُحفَظ في درجة حرارة أقل من ۳۰ درجة مئوية.</p><p dir="RTL">لا تستخدم روزافي بعد انتهاء تاريخ الصلاحية المدون على العبوة. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يجب عدم التَّخلص من الأدوية عن طريق مياه الصرف، أو مع المخلفات المنزلية. اسأل الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد بحاجة إليها. ستُساعد هذه التَّدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; المادة الفعالة هي روزوفاستاتين.</p><p dir="RTL">تحتوي أقراص روزافي ۱۰ ملج المغلَّفة على ۱۰,٤۱٥ ملج روزوفاستاتين الكالسيوم يُعادِل 10 ملج من روزوفاستاتين. تحتوي أقراص روزافي ۲۰ ملج المغلَّفة على ۲۰,۸۳ ملج روزوفاستاتين الكالسيوم يُعادِل۲۰ ملج من روزوفاستاتين.</p><p dir="RTL">&bull; المكونات الأخرى هي:</p><p dir="RTL">كروسبوفيدون، فوسفات الكالسيوم ثلاثي القاعدة، لاكتوز سريع التَّدفق، أفيسيل بدرجة حموضة ۱۰۲ ، ستيرات الماغنسيوم وأوبادري وردي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;روزافي ۱۰ ملج هو أقراص مغلَّفة وردية مستديرة الشكل ثنائية التقعُّر على كلا الجانبين، منقوش على أحد جانبيها .&quot;<strong>SJ 573&quot; </strong></p><p dir="RTL">&bull;روزافي ۲۰ ملج هو أقراص مغلَّفة وردية مستديرة الشَّكل ثنائية التقعُّر على كلا الجانبين، منقوش على أحد جانبيها .&quot;<strong>SJ 575&quot;</strong></p><p dir="RTL">يتوفر روزافي ۱۰ و ۲۰ ملج في عبوات.</p><p dir="RTL">تحتوي جميع العبوات على ۲۸ قرصًا مغلَّفًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ساجا الصيدلانية</p><p dir="RTL">جدة &ndash; المملكة العربية السعودية</p><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية</strong><br />&bull; المملكة العربية السعودية<br />- المركز الوطني للتيقظ والسلامة الدوائية<br />- مركز اتصال هيئة الغذاء والدواء : 19999<br />npc.drug@sfda.gov.sa : - البريد الإلكتروني<br />https://ade.sfda.gov.sa : - الموقع الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس/ 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ROZAVI 10 mg film-coated tablets.
ROZAVI 20 mg film-coated tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ROZAVI 10 mg:
 Each film-coated tablets tablet 10.415 mg rosuvastatin calcium equivalent to 10 mg
rosuvastatin.
 Each film-coated tablets contains 82.82 mg lactose
ROZAVI 20 mg:
 Each film-coated tablets contains 20.83 mg rosuvastatin calcium equivalent to 20 mg
rosuvastatin.
 Each film-coated tablets contains 165.64 mg lactose.
For a full list of excipients, see Section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •		ROZAVI 10 mg is Pink Round Shaped ,biconvex from both sides, film coated tablets embossed with SJ573 on one side.
•		ROZAVI 20 mg is Pink Round Shaped ,biconvex from both sides, film coated tablets embossed with SJ575 on one side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of hypercholesterolaemia<br />Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia<br />(type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type<br />IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g.<br />exercise, weight reduction) is inadequate.<br />Homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering<br />treatments (e.g. LDL apheresis) or if such treatments are not appropriate.<br />Prevention of Cardiovascular Events<br />Prevention of major cardiovascular events in patients who are estimated to have a high risk for<br />a first cardiovascular event (see Section 5.1), as an adjunct to correction of other risk factors.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before treatment initiation the patient should be placed on a standard cholesterol-lowering<br />diet that should continue during treatment. The dose should be individualised according to the<br />goal of therapy and patient response, using current consensus guidelines.<br />Rosuvastatin may be given at any time of day, with or without food.<br />Treatment of hypercholesterolaemia<br />The recommended start dose is 5 or 10 mg orally once daily in both statin na&iuml;ve or patients<br />switched from another HMG CoA reductase inhibitor. The choice of start dose should take into<br />account the individual patient&#39;s cholesterol level and future cardiovascular risk as well as the<br />potential risk for adverse reactions (see below). A dose adjustment to the next dose level can<br />be made after 4 weeks, if necessary (see Section 5.1). In light of the increased reporting rate of<br />adverse reactions with the 40 mg dose compared to lower doses (see Section 4.8), a final<br />titration to the maximum dose of 40 mg should only be considered in patients with severe<br />hypercholesterolaemia at high cardiovascular risk (in particular those with familial<br />hypercholesterolaemia), who do not achieve their treatment goal on 20 mg, and in whom<br />routine follow-up will be performed (see Section 4.4). Specialist supervision is recommended<br />when the 40 mg dose is initiated.<br />Prevention of cardiovascular events<br />In the cardiovascular events risk reduction study, the dose used was 20 mg daily (see Section<br />5.1).<br />Pediatric population<br />Pediatric use should only be carried out by specialists.<br />Children and adolescents 6 to 17 years of age (Tanner Stage &lt;II-V)<br />In children and adolescents with heterozygous familial hypercholesterolaemia the usual start<br />dose is 5 mg daily.<br />&bull; In children 6 to 9 years of age with heterozygous familial hypercholesterolaemia, the usual<br />dose range is 5-10 mg orally once daily. Safety and efficacy of doses greater than 10 mg have<br />not been studied in this population.<br />&bull; In children 10 to 17 years of age with heterozygous familial hypercholesterolaemia, the usual<br />dose range is 5-20 mg orally once daily. Safety and efficacy of doses greater than 20 mg have<br />not been studied in this population.<br />Titration should be conducted according to the individual response and tolerability in pediatric<br />patients, as recommended by the pediatric treatment recommendations (see Section 4.4).<br />Children and adolescents should be placed on standard cholesterol-lowering diet before<br />rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.<br />Experience in children with homozygous familial hypercholesterolaemia is limited to a small<br />number of children aged between 8 and 17 years.<br />Children younger than 6 years<br />The safety and efficacy of use in children younger than 6 years has not been studied. Therefore,<br />Rosuvastatin is not recommended for use in children younger than 6 years.<br />Use in the elderly<br />A start dose of 5 mg is recommended in patients &gt;70 years (see Section 4.4). No other dose<br />adjustment is necessary in relation to age.<br />Dosage in patients with renal insufficiency<br />No dose adjustment is necessary in patients with mild to moderate renal impairment. The<br />recommended start dose is 5 mg in patients with moderate renal impairment (creatinine<br />clearance of &lt;60 ml/min). The 40 mg dose is contraindicated in patients with moderate renal<br />impairment. The use of Rosuvastatin in patients with severe renal impairment is<br />contraindicated for all doses (see Section 4.3 and Section 5.2).<br />Dosage in patients with hepatic impairment<br />There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh scores<br />of 7 or below. However, increased systemic exposure has been observed in subjects with ChildPugh scores of 8 and 9 (see Section 5.2). In these patients an assessment of renal function<br />should be considered (see Section 4.4). There is no experience in subjects with Child-Pugh<br />scores above 9. Rosuvastatin is contraindicated in patients with active liver disease (see Section<br />4.3).<br />Race<br />Increased systemic exposure has been seen in Asian subjects (see Section 4.3, Section 4.4 and<br />Section 5.2). The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg<br />dose is contraindicated in these patients.<br />Genetic polymorphisms<br />Specific types of genetic polymorphisms are known that can lead to increased rosuvastatin<br />exposure (see Section 5.2). For patients who are known to have such specific types of<br />polymorphisms, a lower daily dose of Rosuvastatin is recommended.<br />Dosage in patients with pre-disposing factors to myopathy<br />The recommended start dose is 5 mg in patients with predisposing factors to myopathy (see<br />Section 4.4).<br />The 40 mg dose is contraindicated in some of these patients (see Section 4.3).<br />Concomitant therapy<br />Rosuvastatin is a substrate of various transporter proteins (e.g. OATP1B1 and BCRP). The risk of<br />myopathy (including rhabdomyolysis) is increased when Rosuvastatin is administered<br />concomitantly with certain medicinal products that may increase the plasma concentration of<br />rosuvastatin due to interactions with these transporter proteins (e.g. ciclosporin and certain<br />protease inhibitors including combinations of ritonavir with atazanavir, lopinavir, and/or<br />tipranavir; see Sections 4.4 and 4.5). Whenever possible, alternative medications should be<br />considered, and, if necessary, consider temporarily discontinuing Rosuvastatin therapy. In<br />situations where co-administration of these medicinal products with Rosuvastatin is<br />unavoidable, the benefit and the risk of concurrent treatment and Rosuvastatin dosing<br />adjustments should be carefully considered (see Section 4.5).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rosuvastatin is contraindicated:
- in patients with hypersensitivity to rosuvastatin or to any of the excipients.
- in patients with active liver disease including unexplained, persistent elevations of serum
transaminases and any serum transaminase elevation exceeding 3 x the upper limit of normal
(ULN).
- in patients with severe renal impairment (creatinine clearance <30 ml/min).
- in patients with myopathy.
- in patients receiving concomitant ciclosporin.
- During pregnancy and lactation and in women of childbearing potential not using appropriate
contraceptive measures.
The 40 mg dose is contraindicated in patients with pre-disposing factors for
myopathy/rhabdomyolysis. Such factors include:
− moderate renal impairment (creatinine clearance < 60 ml/min)
− hypothyroidism
− personal or family history of hereditary muscular disorders
− previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate
− alcohol abuse− situations where an increase in plasma levels may occur
− Asian patients
− concomitant use of fibrates.
(See Sections 4.4, 4.5 and 5.2)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In few cases, statins have been reported to induce de novo or aggravate pre-existing myasthenia gravis or ocular myasthenia (see section 4.8). Rozavi should be discontined in case of aggravation of symptoms. Recurrences when the same or a different statin was (re-) administered have been reported.</p><p>Renal Effects<br />Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in<br />patients treated with higher doses of Rosuvastatin where it was transient or intermittent in<br />most cases. Proteinuria has not been shown to be predictive of acute or progressive renal<br />disease (see Section 4.8). The reporting rate for serious renal events in post-marketing use is<br />higher at the 40 mg dose. An assessment of renal function should be considered during routine<br />follow-up of patients treated with a dose of 40 mg.<br />Skeletal Muscle Effects<br />Effects on skeletal muscle e.g. myalgia, myopathy and, rarely, rhabdomyolysis have been<br />reported in Rosuvastatin -treated patients with all doses and in particular with doses &gt; 20 mg.<br />Very rare cases of rhabdomyolysis have been reported with the use of ezetimibe in<br />combination with HMG-CoA reductase inhibitors. A pharmacodynamic interaction cannot be<br />excluded (see Section 4.5) and caution should be exercised with their combined use.<br />As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis associated<br />with Rosuvastatin in post-marketing use is higher at the 40 mg dose.<br />Creatine Kinase Measurement<br />Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence of<br />a plausible alternative cause of CK increase which may confound interpretation of the result. If<br />CK levels are significantly elevated at baseline (&gt;5xULN) a confirmatory test should be carried<br />out within 5 &ndash; 7 days. If the repeat test confirms a baseline CK &gt;5xULN, treatment should not be<br />started.<br />Before Treatment<br />Rosuvastatin, as with other HMG-CoA reductase inhibitors, should be prescribed with caution in<br />patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include:<br />&bull; renal impairment<br />&bull; hypothyroidism<br />&bull; personal or family history of hereditary muscular disorders<br />&bull; previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate<br />&bull; alcohol abuse<br />&bull; age &gt;70 years<br />&bull; situations where an increase in plasma levels may occur (see Sections 4.2, 4.5 and 5.2)<br />&bull; concomitant use of fibrates.<br />In such patients the risk of treatment should be considered in relation to possible benefit and<br />clinical monitoring is recommended. If CK levels are significantly elevated at baseline (&gt;5xULN)<br />treatment should not be started.<br />Whilst on Treatment<br />Patients should be asked to report inexplicable muscle pain, weakness or cramps immediately,<br />particularly if associated with malaise or fever. CK levels should be measured in these patients.<br />Therapy should be discontinued if CK levels are markedly elevated (&gt;5xULN) or if muscular<br />symptoms are severe and cause daily discomfort (even if CK levels are &le; 5x ULN). If symptoms<br />resolve and CK levels return to normal, then consideration should be given to re-introducing<br />Rosuvastatin or an alternative HMG-CoA reductase inhibitor at the lowest dose with close<br />monitoring. Routine monitoring of CK levels in asymptomatic patients is not warranted. There<br />have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or<br />after treatment with statins, including rosuvastatin. IMNM is clinically characterised by<br />proximal muscle weakness and elevated serum creatine kinase, which persist despite<br />discontinuation of statin treatment.<br />In clinical trials there was no evidence of increased skeletal muscle effects in the small number<br />of patients dosed with Rosuvastatin and concomitant therapy. However, an increase in the<br />incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA<br />reductase inhibitors together with fibric acid derivatives including gemfibrozil, ciclosporin,<br />nicotinic acid, azole antifungals, protease inhibitors and macrolide antibiotics. Gemfibrozil<br />increases the risk of myopathy when given concomitantly with some HMG-CoA reductase<br />inhibitors. Therefore, the combination of Rosuvastatin and gemfibrozil is not recommended.<br />The benefit of further alterations in lipid levels by the combined use of Rosuvastatin with<br />fibrates or niacin should be carefully weighed against the potential risks of such combinations.<br />The 40 mg dose is contraindicated with concomitant use of a fibrate (see Section 4.5 and<br />Section 4.8).<br />Combination with rosuvastatin and fusidic acid is not recommended. There have been reports<br />of rhabdomyolysis (including some fatalities) in patients receiving this combination (see Section<br />4.5).<br />Rosuvastatin should not be used in any patient with an acute, serious condition suggestive of<br />myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis<br />(e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte<br />disorders; or uncontrolled seizures).<br />Liver Effects<br />As with other HMG-CoA reductase inhibitors, Rosuvastatin should be used with caution in<br />patients who consume excessive quantities of alcohol and/or have a history of liver disease.<br />It is recommended that liver function tests be carried out prior to, and 3 months following, the<br />initiation of treatment. Rosuvastatin should be discontinued or the dose reduced if the level of<br />serum transaminases is greater than 3 times the upper limit of normal. The reporting rate for<br />serious hepatic events (consisting mainly of increased hepatic transaminases) in post-marketing<br />use is higher at the 40 mg dose.<br />In patients with secondary hypercholesterolaemia caused by hypothyroidism or nephrotic<br />syndrome, the underlying disease should be treated prior to initiating therapy with<br />Rosuvastatin.<br />Race<br />Pharmacokinetic studies show an increase in exposure in Asian subjects compared with<br />Caucasians (see Section 4.2, Section 4.3 and Section 5.2).<br />Protease inhibitors<br />Increased systemic exposure to rosuvastatin has been observed in subjects receiving<br />rosuvastatin concomitantly with various protease inhibitors in combination with ritonavir.<br />Consideration should be given both to the benefit of lipid lowering by use of Rosuvastatin in<br />HIV patients receiving protease inhibitors and the potential for increased rosuvastatin plasma<br />concentrations when initiating and up titrating Rosuvastatin doses in patients treated with<br />protease inhibitors. The concomitant use with certain protease inhibitors is not recommended<br />unless the dose of Rosuvastatin is adjusted (see Sections 4.2 and 4.5).<br />Lactose intolerance<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or<br />glucose-galactose malabsorption should not take this medicine.<br />Interstitial lung disease<br />Exceptional cases of interstitial lung disease have been reported with some statins, especially<br />with long term therapy (see Section 4.8). Presenting features can include dyspnoea, nonproductive cough and deterioration in general health (fatigue, weight loss and fever). If it is<br />suspected a patient has developed interstitial lung disease, statin therapy should be<br />discontinued.<br />Diabetes Mellitus<br />Some evidence suggests that statins as a class raise blood glucose and in some patients, at high<br />risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is<br />appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and<br />therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose<br />5.6 to 6.9 mmol/l, BMI &gt;30 kg/m2, raised triglycerides, hypertension) should be monitored both<br />clinically and biochemically according to national guidelines.<br />In the JUPITER study, the reported overall frequency of diabetes mellitus was 2.8% in<br />rosuvastatin and 2.3% in placebo, mostly in patients with fasting glucose 5.6 to 6.9 mmol/l.<br />Pediatric population<br />The evaluation of linear growth (height), weight, BMI (body mass index), and secondary<br />characteristics of sexual maturation by Tanner staging in pediatric patients 6 to 17 years of age<br />taking rosuvastatin is limited to a two-year period. After two years of study treatment, no effect<br />on growth, weight, BMI or sexual maturation was detected (see Section 5.1).<br />In a clinical trial of children and adolescents receiving rosuvastatin for 52 weeks, CK elevations<br />&gt;10xULN and muscle symptoms following exercise or increased physical activity were observed<br />more frequently compared to observations in clinical trials in adults (see Section 4.8).</p><p>Severe cutaneous adverse reactions Severe cutaneous adverse reactions including Stevens- Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be life-threatening or fatal, have been reported with rosuvastatin. At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions and be closely monitored. If signs and symptoms suggestive of this reaction appears, Rosuvastatin Film-coated tablets should be discontinued immediately and an alternative treatment should be considered. If the patient has developed a serious reaction such as SJS or DRESS with the use of Rosuvastatin Film-coated tablets, treatment with Rosuvastatin Filmcoated tablets must not be restarted in this patient at any time.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of co-administered medicinal products on rosuvastatin<br />Transporter protein inhibitors: Rosuvastatin is a substrate for certain transporter proteins<br />including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant<br />administration of Rosuvastatin with medicinal products that are inhibitors of these transporter<br />proteins may result in increased rosuvastatin plasma concentrations and an increased risk of<br />myopathy (see Sections 4.2, 4.4 and 4.5 Table 1).<br />Ciclosporin: During concomitant treatment with Rosuvastatin and ciclosporin, rosuvastatin AUC<br />values were on average 7 times higher than those observed in healthy volunteers (see Table 1).<br />Rosuvastatin is contraindicated in patients receiving concomitant ciclosporin (see Section 4.3).<br />Concomitant administration did not affect plasma concentrations of ciclosporin.<br />Protease inhibitors: Although the exact mechanism of interaction is unknown, concomitant<br />protease inhibitor use may strongly increase rosuvastatin exposure (see Table 1). For instance,<br />in a pharmacokinetic study, co-administration of 10 mg rosuvastatin and a combination product<br />of two protease inhibitors (300 mg atazanavir / 100 mg ritonavir) in healthy volunteers was<br />associated with an approximately three-fold and seven-fold increase in rosuvastatin AUC and<br />Cmax respectively. The concomitant use of Rosuvastatin and some protease inhibitor<br />combinations may be considered after careful consideration of Rosuvastatin dose adjustments<br />based on the expected increase in rosuvastatin exposure (see Sections 4.2, 4.4 and 4.5 Table 1).<br />Gemfibrozil and other lipid-lowering products: Concomitant use of Rosuvastatin and<br />gemfibrozil resulted in a 2-fold increase in rosuvastatin C max and AUC (see Section 4.4).<br />Based on data from specific interaction studies no pharmacokinetic relevant interaction with<br />fenofibrate is expected, however a pharmacodynamic interaction may occur. Gemfibrozil,<br />fenofibrate, other fibrates and lipid lowering doses (&gt; or equal to 1g/day) of niacin (nicotinic<br />acid) increase the risk of myopathy when given concomitantly with HMG-CoA reductase<br />inhibitors, probably because they can produce myopathy when given alone. The 40 mg dose is<br />contraindicated with concomitant use of a fibrate (see Sections 4.3 and 4.4). These patients<br />should also start with the 5 mg dose.<br />Ezetimibe: Concomitant use of 10 mg Rosuvastatin and 10 mg ezetimibe resulted in a 1.2 fold<br />increase in AUC of rosuvastatin in hypercholesterolaemic subjects (Table 1). A<br />pharmacodynamic interaction, in terms of adverse effects, between Rosuvastatin and ezetimibe<br />cannot be ruled out (see Section 4.4).<br />Antacid: The simultaneous dosing of Rosuvastatin with an antacid suspension containing<br />aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma<br />concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2<br />hours after Rosuvastatin. The clinical relevance of this interaction has not been studied.<br />Erythromycin: Concomitant use of Rosuvastatin and erythromycin resulted in a 20% decrease in<br />AUC and a 30% decrease in Cmax of rosuvastatin. This interaction may be caused by the increase<br />in gut motility caused by erythromycin.<br />Cytochrome P450 enzymes: Results from in vitro and in vivo studies show that rosuvastatin is<br />neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is<br />a poor substrate for these isoenzymes. Therefore, drug interactions resulting from cytochrome<br />P450-mediated metabolism are not expected. No clinically relevant interactions have been<br />observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or<br />ketoconazole (an inhibitor of CYP2A6 and CYP3A4).<br />Interactions requiring rosuvastatin dose adjustments (see also Table 1): When it is necessary<br />to co-administer Rosuvastatin with other medicinal products known to increase exposure to<br />rosuvastatin, doses of Rosuvastatin should be adjusted. Start with a 5 mg once daily dose of<br />Rosuvastatin if the expected increase in exposure (AUC) is approximately 2-fold or higher. The<br />maximum daily dose of Rosuvastatin should be adjusted so that the expected rosuvastatin<br />exposure would not likely exceed that of a 40 mg daily dose of Rosuvastatin taken without<br />interacting medicinal products, for example a 20 mg dose of Rosuvastatin with gemfibrozil (1.9-<br />fold increase), and a 10 mg dose of Rosuvastatin with combination ritonavir/atazanavir (3.1-fold<br />increase).<br /><img alt="" width="540" height="624" src="data:image/png;base64,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" /></p><p>Vitamin K antagonists: As with other HMG-CoA reductase inhibitors, the initiation of treatment<br />or dosage up-titration of Rosuvastatin in patients treated concomitantly with vitamin K<br />antagonists (e.g. warfarin or another coumarin anticoagulant) may result in an increase in<br />International Normalised Ratio (INR). Discontinuation or down-titration of Rosuvastatin may<br />result in a decrease in INR. In such situations, appropriate monitoring of INR is desirable.<br />Oral contraceptive/hormone replacement therapy (HRT): Concomitant use of Rosuvastatin<br />and an oral contraceptive resulted in an increase in ethinyl estradiol and norgestrel AUC of 26%<br />and 34%, respectively. These increased plasma levels should be considered when selecting oral<br />contraceptive doses. There are no pharmacokinetic data available in subjects taking<br />concomitant Rosuvastatin and HRT and therefore a similar effect cannot be excluded. However,<br />the combination has been extensively used in women in clinical trials and was well tolerated.<br />Other medicinal products:<br />Digoxin: Based on data from specific interaction studies no clinically relevant interaction with<br />digoxin is expected.<br />Fusidic Acid: Interaction studies with rosuvastatin and fusidic acid have not been conducted. As<br />with other statins, muscle related events, including rhabdomyolysis, have been reported in<br />post-marketing experience with rosuvastatin and fusidic acid given concurrently.<br />Therefore, the combination rosuvastatin and fusidic acid is not recommended. If possible,<br />temporary suspension of rosuvastatin treatment is recommended. If unavoidable, patients<br />should be closely monitored.<br />Pediatric population: Interaction studies have only been performed in adults. The extent of<br />interactions in the pediatric population is not known.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy Category: X</p><p>Rozavi Film-coated tablets are contraindicated in pregnancy and lactation.</p><p>Women of child bearing potential should use appropriate contraceptive measures. Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the fetus, the potential risk from inhibition of HMGCoA reductase outweighs the advantage of treatment during pregnancy.</p><p>&nbsp;If a patient becomes pregnant during use of this product, treatment should be discontinued immediately.</p><p>Breast-feeding</p><p>Rosuvastatin is excreted in the milk of rats. There are no data with respect to excretion in milk in humans.</p><p>Fertility</p><p>No data is available on the effects of rosuvastatin on human fertility. Animal studies provide limited evidence of reproductive toxicity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies to determine the effect of Rosuvastatin on the ability to drive and use machines have<br />not been conducted. However, based on its pharmacodynamic properties, Rosuvastatin is<br />unlikely to affect this ability. When driving vehicles or operating machines, it should be taken<br />into account that dizziness may occur during treatment.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety:</u></p><p>&nbsp;</p><p>The adverse reactions seen with Rosuvastatin are generally mild and transient. In controlled clinical trials, less than 4% of Rosuvastatin -treated patients were withdrawn due to adverse reactions.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions:</u></p><p>&nbsp;</p><p>Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for rosuvastatin. Adverse reactions listed below are classified according to frequency and system organ class (SOC).</p><p>The frequencies of adverse reactions are ranked according to the following convention: Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Table 2. Adverse reactions based on data from clinical studies and post-marketing experience</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Blood</em><em> </em><em>and</em><em> </em><em>lymphatic system disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions including angioedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Endocrine disorders</em></p></td><td style="vertical-align:top"><p>Diabetes mellitus<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system</em></p></td><td style="vertical-align:top"><p>Headache</p></td><td rowspan="8" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="8" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Polyneuropathy</p></td><td style="vertical-align:top"><p>Peripheral</p></td></tr><tr><td style="vertical-align:top"><p><em>disorders</em></p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Memory loss</p></td><td style="vertical-align:top"><p>neuropathy</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sleep</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>disturbances</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(including</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>insomnia and</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>nightmares)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myasthenia gravis</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough Dyspnea</p></td></tr><tr><td style="vertical-align:top"><p><em>Eyes</em><em> </em><em>Disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ocular myasthenia</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastro-intestinal</em><em> </em><em>disorders</em></p></td><td style="vertical-align:top"><p>Constipation Nausea Abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diarrhea</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary</em><em> </em><em>disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased hepatic transaminases</p></td><td style="vertical-align:top"><p>Jaundice Hepatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritis Rash Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens- Johnson syndrome</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculo-skeletal</em><em> </em><em>and connective tissue disorders</em></p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myopathy (including myositis) Rhabdomyolysis</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Tendon disorders, sometimes complicated by rupture Immune- mediated necrotising myopathy</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal and urinary</em><em> </em><em>disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oedema</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>1</sup> Frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge; 5.6 mmol/L, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, history of hypertension).</p></td></tr></tbody></table><p>As with other HMG-CoA reductase inhibitors, the incidence of adverse drug reactions tends to be dose dependent.</p><p>&nbsp;</p><p><u>Description of selected AE:</u></p><p>&nbsp;</p><p><strong>Renal effects: </strong>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with Rosuvastatin. Shifts in urine protein from none or trace to ++ or more were seen in &lt;1% of patients at some time during treatment with 10 and 20 mg , and in approximately 3% of patients treated with 40 mg.. A minor increase in shift from none or trace</p><p>&nbsp;</p><p>to + was observed with the 20 mg dose. In most cases, proteinuria decreases or disappears spontaneously on continued therapy. Review of data from clinical trials and post-marketing experience to date has not identified a causal association between proteinuria and acute or progressive renal disease.</p><p>Haematuria has been observed in patients treated with Rosuvastatin and clinical trial data show that the occurrence is low.</p><p>&nbsp;</p><p><strong>Skeletal muscle effects: </strong>Effects on skeletal muscle e.g. myalgia, myopathy (including myositis) and, rarely, rhabdomyolysis with and without acute renal failure have been reported in Rosuvastatin treated patients with all doses and in particular with doses &gt; 20 mg.</p><p>&nbsp;</p><p>A dose-related increase in CK levels has been observed in patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient. If CK levels are elevated (&gt;5xULN), treatment should be discontinued (see Section 4.4).</p><p>&nbsp;</p><p><strong>Liver effects: </strong>As with other HMG-CoA reductase inhibitors, a dose-related increase in transaminases has been observed in a small number of patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient.</p><p>The following adverse events have been reported with some statins: Sexual dysfunction.</p><p>Exceptional cases of interstitial lung disease, especially with long term therapy (see Section 4.4).</p><p>&nbsp;</p><p>The reporting rates for rhabdomyolysis, serious renal events and serious hepatic events (consisting mainly of increased hepatic transaminases) is higher at the 40 mg dose.</p><p>&nbsp;</p><p><u>Pediatric population:</u></p><p>&nbsp;</p><p>Creatine kinase elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently in a 52-week clinical trial of children and adolescents compared to adults (see Section 4.4). In other respects, the safety profile of rosuvastatin was similar in children and adolescents compared to adults.</p><p>&nbsp;</p><p><u>Other special population:</u></p><p>&nbsp;</p><p>Use in the elderly</p><p>A start dose of 5 mg is recommended in patients &gt;70 years (see Section 4.4). No other dose adjustment is necessary in relation to age</p><p>-To report any side effect (s)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
  left:0;text-align:left;margin-left:66.35pt;margin-top:24.35pt;width:479.4pt;
  height:17.2pt;text-indent:0;z-index:-15728128;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page' filled="f"
  strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:1.25pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.4pt;margin-bottom:.0001pt'><b style='mso-bidi-font-weight:
     normal'><span style='font-size:12.0pt;mso-bidi-font-size:11.0pt'>-<span
     style='letter-spacing:-.2pt'> </span>National Pharmacovigilance Center
     (NPC)<o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="646" height="29" alt="Text Box: - National Pharmacovigilance Center (NPC)" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>Saudi Arabia :</strong>&nbsp; &nbsp; &nbsp;&nbsp;<!--[if gte vml 1]><v:shape
 id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:67.45pt;margin-top:-70.45pt;width:479.4pt;
 height:75.75pt;text-indent:0;z-index:15730688;
 mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>-&nbsp; SFDA Call Center: 19999</p><p>-&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table></td></tr></tbody></table><p><strong>United Arab Emirates</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1028" type="#_x0000_t202" style='position:absolute;margin-left:66.4pt;
  margin-top:14.35pt;width:528.45pt;height:73.85pt;z-index:-15727616;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".16936mm">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:240.0pt;
     margin-bottom:0in;margin-left:32.1pt;margin-bottom:.0001pt'>Pharmacovigilance<span
     style='letter-spacing:-.35pt'> </span>&amp;<span style='letter-spacing:
     -.55pt'> </span>Medical<span style='letter-spacing:-.4pt'> </span>Device<span
     style='letter-spacing:-.55pt'> </span>section<span style='letter-spacing:
     -2.55pt'> </span>P.O.Box: 1853<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.15pt;margin-right:0in;margin-bottom:
     0in;margin-left:32.1pt;margin-bottom:.0001pt'>Tel:<span style='letter-spacing:
     -.25pt'> </span>80011111<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:32.1pt'>Email<span
     style='letter-spacing:-.4pt'> </span>:<span style='letter-spacing:-.5pt'> </span><a
     href="mailto:pv@mohap.gov.ae"><span style='color:windowtext;text-decoration:
     none;text-underline:none'>pv@mohap.gov.ae</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:32.1pt'>Drug<span
     style='letter-spacing:-.45pt'> </span>Department<span style='letter-spacing:
     -.15pt'> </span>Ministry<span style='letter-spacing:.05pt'> </span>of<span
     style='letter-spacing:-.15pt'> </span>Health<span style='letter-spacing:
     -.2pt'> </span>&amp;<span style='letter-spacing:-.2pt'> </span>Prevention<span
     style='letter-spacing:-.15pt'> </span>Dubai –<span style='letter-spacing:
     -.15pt'> </span>UAE<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="710" height="104" alt="Text Box: Pharmacovigilance &amp; Medical Device section P.O.Box: 1853
Tel: 80011111
Email : pv@mohap.gov.ae
Drug Department Ministry of Health &amp; Prevention Dubai – UAE
" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states /other countries</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1029" type="#_x0000_t202" style='position:absolute;margin-left:102.4pt;
  margin-top:10.7pt;width:443.4pt;height:17.2pt;z-index:-15727104;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:1.2pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.35pt;margin-bottom:.0001pt'>-Please<span
     style='letter-spacing:-.25pt'> </span>contact<span style='letter-spacing:
     -.35pt'> </span>the<span style='letter-spacing:-.1pt'> </span>relevant<span
     style='letter-spacing:-.15pt'> </span>competent<span style='letter-spacing:
     -.25pt'> </span>authority.<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="597" height="29" alt="Text Box: -Please contact the relevant competent authority." src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of overdose. In the event of overdose, the patient<br />should be treated symptomatically and supportive measures instituted as required. Liver<br />function and CK levels should be monitored. Haemodialysis is unlikely to be of benefit.<br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: HMG-CoA reductase inhibitors<br />ATC code: C10A A07<br />Mechanism of action<br />Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting<br />enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for<br />cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for<br />cholesterol lowering.<br />Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing<br />uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the<br />total number of VLDL and LDL particles.<br />Pharmacodynamic effects<br />Rosuvastatin reduces elevated LDL-cholesterol, total cholesterol and triglycerides and increases<br />HDL-cholesterol. It also lowers ApoB, nonHDL-C, VLDL-C, VLDL-TG and increases ApoA-I (see<br />Table 3). Rosuvastatin also lowers the LDL-C/HDL-C, total C/HDL-C and nonHDL-C/HDL-C and<br />the ApoB/ApoA-I ratios.<br />Table 3 Dose response in patients with primary hypercholesterolaemia (type IIa and IIb)<br />(adjusted mean percent change from baseline)<br /><img alt="" width="535" height="165" src="data:image/png;base64,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" /></p><p>Clinical efficacy and safety<br />Rosuvastatin is effective in adults with hypercholesterolaemia, with and without<br />hypertriglyceridaemia, regardless of race, sex, or age and in special populations such as<br />diabetics, or patients with familial hypercholesterolaemia.<br />From pooled phase III data, Rosuvastatin has been shown to be effective at treating the<br />majority of patients with type IIa and IIb hypercholesterolaemia (mean baseline LDL-C about 4.8<br />mmol/l) to recognised European Atherosclerosis Society (EAS; 1998) guideline targets; about<br />80% of patients treated with 10 mg reached the EAS targets for LDL-C levels (&lt;3 mmol/l).<br />In a large study, 435 patients with heterozygous familial hypercholesterolaemia were given<br />Rosuvastatin from 20 mg to 80 mg in a force-titration design. All doses showed a beneficial<br />effect on lipid parameters and treatment to target goals. Following titration to a daily dose of<br />40 mg (12 weeks of treatment), LDL-C was reduced by 53%. 33% of patients reached EAS<br />guidelines for LDL-C levels (&lt;3 mmol/l).<br />In a force-titration, open label trial, 42 patients with homozygous familial<br />hypercholesterolaemia were evaluated for their response to Rosuvastatin 20 - 40 mg. In the<br />overall population, the mean LDL-C reduction was 22%.<br />In clinical studies with a limited number of patients, Ruso has been shown to have additive<br />efficacy in lowering triglycerides when used in combination with fenofibrate and in increasing<br />HDL-C levels when used in combination with niacin (see Section 4.4).<br />In a multi-centre, double-blind, placebo-controlled clinical study (METEOR), 984 patients<br />between 45 and 70 years of age and at low risk for coronary heart disease (defined as<br />Framingham risk &lt;10% over 10 years), with a mean LDL-C of 4.0 mmol/l (154.5 mg/dL), but with<br />subclinical atherosclerosis (detected by Carotid Intima Media Thickness) were randomised to 40<br />mg rosuvastatin once daily or placebo for 2 years. Rosuvastatin significantly slowed the rate of<br />progression of the maximum CIMT for the 12 carotid artery sites compared to placebo by -<br />0.0145 mm/year [95% confidence interval -0.0196, -0.0093; p&lt;0.0001]. The change from<br />baseline was -0.0014 mm/year (-0.12%/year (non-significant)) for rosuvastatin compared to a<br />progression of +0.0131 mm/year (1.12%/year (p&lt;0.0001)) for placebo. No direct correlation<br />between CIMT decrease and reduction of the risk of cardiovascular events has yet been<br />demonstrated. The population studied in METEOR is low risk for coronary heart disease and<br />does not represent the target population of rosuvastatin 40mg. The 40mg dose should only be<br />prescribed in patients with severe hypercholesterolaemia at high cardiovascular risk (see<br />Section 4.2).<br />In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating<br />Rosuvastatin (JUPITER) study, the effect of rosuvastatin on the occurrence of major<br />atherosclerotic cardiovascular disease events was assessed in 17,802 men (&ge;50 years) and<br />women (&ge;60 years).<br />Study participants were randomly assigned to placebo (n=8901) or rosuvastatin 20 mg once<br />daily (n=8901) and were followed for a mean duration of 2 years.<br />LDL-cholesterol concentration was reduced by 45% (p&lt;0.001) in the rosuvastatin group<br />compared to the placebo group.<br />In a post-hoc analysis of a high-risk subgroup of subjects with a baseline Framingham risk score<br />&gt;20% (1558 subjects) there was a significant reduction in the combined end-point of<br />cardiovascular death, stroke and myocardial infarction (p=0.028) on rosuvastatin treatment<br />versus placebo. The absolute risk reduction in the event rate per 1000 patient-years was 8.8.<br />Total mortality was unchanged in this high risk group (p=0.193). In a post-hoc analysis of a highrisk subgroup of subjects (9302 subjects total) with a baseline SCORE risk &ge;5% (extrapolated to<br />include subjects above 65 yrs) there was a significant reduction in the combined end-point of<br />cardiovascular death, stroke and myocardial infarction (p=0.0003) on rosuvastatin treatment<br />versus placebo. The absolute risk reduction in the event rate was 5.1 per 1000 patient-years.<br />Total mortality was unchanged in this high risk group (p=0.076).<br />In the JUPITER trial there were 6.6% of rosuvastatin and 6.2% of placebo subjects who<br />discontinued use of study medication due to an adverse event. The most common adverse<br />events that led to treatment discontinuation were: myalgia (0.3% rosuvastatin, 0.2% placebo),<br />abdominal pain (0.03% rosuvastatin, 0.02% placebo) and rash (0.02% rosuvastatin, 0.03%<br />placebo). The most common adverse events at a rate greater than or equal to placebo were<br />urinary tract infection (8.7% rosuvastatin, 8.6% placebo), nasopharyngitis (7.6% rosuvastatin,<br />7.2% placebo), back pain (7.6% rosuvastatin, 6.9% placebo) and myalgia (7.6% rosuvastatin,<br />6.6% placebo).<br />Pediatric population<br />In a double-blind, randomized, multi-centre, placebo-controlled, 12-week study (n=176, 97<br />male and 79 female) followed by a 40-week (n=173, 96 male and 77 female), open-label,<br />rosuvastatin dose-titration phase, patients 10-17 years of age (Tanner stage II-V, females at<br />least 1 year post-menarche) with heterozygous familial hypercholesterolaemia received<br />rosuvastatin 5, 10 or 20 mg or placebo daily for 12 weeks and then all received rosuvastatin<br />daily for 40 weeks. At study entry, approximately 30% of the patients were 10-13 years and<br />approximately 17%, 18%, 40%, and 25% were Tanner stage II, III, IV, and V, respectively.<br />LDL-C was reduced 38.3%, 44.6%, and 50.0% by rosuvastatin 5, 10 and 20 mg, respectively,<br />compared to 0.7% for placebo.<br />At the end of the 40-week, open-label, titration to goal, dosing up to a maximum of 20 mg once<br />daily, 70 of 173 patients (40.5%) had achieved the LDL-C goal of less than 2.8 mmol/l.<br />After 52 weeks of study treatment, no effect on growth, weight, BMI or sexual maturation was<br />detected (see Section 4.4). This trial (n=176) was not suited for comparison of rare adverse drug<br />events.<br />Rosuvastatin was also studied in a 2-year open-label, titration-to-goal study in 198 children with<br />heterozygous familial hypercholesterolaemia aged 6 to 17 years (88 male and 110 female,<br />Tanner stage &lt;II-V). The starting dose for all patients was 5 mg rosuvastatin once daily. Patients<br />aged 6 to 9 years (n=64) could titrate to a maximum dose of 10 mg once daily and patients aged<br />10 to 17 years (n=134) to a maximum dose of 20 mg once daily.<br />After 24 months of treatment with rosuvastatin, the LS mean percent reduction from the<br />baseline value in LDL-C was -43% (Baseline: 236 mg/dL, Month 24: 133 mg/dL). For each age<br />group, the LS mean percent reductions from baseline values in LDL-C were -43% (Baseline: 234<br />mg/dL, Month 24: 124 mg/dL), -45% (Baseline: 234 mg/dL, 124 mg/dL), and -35% (Baseline: 241<br />mg/dL, Month 24: 153 mg/dL) in the 6 to &lt;10, 10 to &lt;14, and 14 to &lt;18 age groups,<br />respectively.<br />Rosuvastatin 5 mg, 10 mg, and 20 mg also achieved statistically significant mean changes from<br />baseline for the following secondary lipid and lipoprotein variables: HDL-C, TC, non-HDL-C, LDLC/HDL-C, TC/HDL-C, TG/HDL-C, non-HDL-C/HDL-C, ApoB, ApoB/ApoA-1. These changes were<br />each in the direction of improved lipid responses and were sustained over 2 years.<br />No effect on growth, weight, BMI or sexual maturation was detected after 24 months of<br />treatment (see Section 4.4).<br />The European Medicines Agency has waived the obligation to submit the results of studies with<br />rosuvastatin in all subsets of the pediatric population in the treatment of homozygous familial<br />hypercholesterolaemia, primary combined (mixed) dyslipidaemia and in the prevention of<br />cardiovascular events (see Section 4.2 for information on pediatric use).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption: Maximum rosuvastatin plasma concentrations are achieved approximately 5 hours<br />after oral administration. The absolute bioavailability is approximately 20%.<br />Distribution: Rosuvastatin is taken up extensively by the liver which is the primary site of<br />cholesterol synthesis and LDL-C clearance. The volume of distribution of rosuvastatin is<br />approximately 134 L. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to<br />albumin.<br />Metabolism: Rosuvastatin undergoes limited metabolism (approximately 10%). In vitro<br />metabolism studies using human hepatocytes indicate that rosuvastatin is a poor substrate for<br />cytochrome P450-based metabolism. CYP2C9 was the principal isoenzyme involved, with 2C19,<br />3A4 and 2D6 involved to a lesser extent. The main metabolites identified are the N-desmethyl<br />and lactone metabolites. The N-desmethyl metabolite is approximately 50% less active than<br />rosuvastatin whereas the lactone form is considered clinically inactive. Rosuvastatin accounts<br />for greater than 90% of the circulating HMG-CoA reductase inhibitor activity.<br />Excretion: Approximately 90% of the rosuvastatin dose is excreted unchanged in the faeces<br />(consisting of absorbed and non-absorbed active substance) and the remaining part is excreted<br />in urine. Approximately 5% is excreted unchanged in urine. The plasma elimination half-life is<br />approximately 19 hours. The elimination half-life does not increase at higher doses. The<br />geometric mean plasma clearance is approximately 50 litres/hour (coefficient of variation<br />21.7%). As with other HMG-CoA reductase inhibitors, the hepatic uptake of rosuvastatin<br />involves the membrane transporter OATP-C. This transporter is important in the hepatic<br />elimination of rosuvastatin.<br />Linearity: Systemic exposure of rosuvastatin increases in proportion to dose. There are no<br />changes in pharmacokinetic parameters following multiple daily doses.<br />Special populations:<br />Age and sex: There was no clinically relevant effect of age or sex on the pharmacokinetics of<br />rosuvastatin in adults. The pharmacokinetics of rosuvastatin in children and adolescents with<br />heterozygous familial hypercholesterolaemia was similar to that of adult volunteers (see<br />&ldquo;Pediatric population&rdquo; below).<br />Race: Pharmacokinetic studies show an approximate 2-fold elevation in median AUC and Cmax in<br />Asian subjects (Japanese, Chinese, Filipino, Vietnamese and Koreans) compared with<br />Caucasians; Asian-Indians show an approximate 1.3-fold elevation in median AUC and Cmax. A<br />population pharmacokinetic analysis revealed no clinically relevant differences in<br />pharmacokinetics between Caucasian and Black groups.<br />Renal insufficiency: In a study in subjects with varying degrees of renal impairment, mild to<br />moderate renal disease had no influence on plasma concentration of rosuvastatin or the Ndesmethyl metabolite. Subjects with severe impairment (CrCl &lt;30 ml/min) had a 3-fold increase<br />in plasma concentration and a 9-fold increase in the N-desmethyl metabolite concentration<br />compared to healthy volunteers. Steady-state plasma concentrations of rosuvastatin in subjects<br />undergoing haemodialysis were approximately 50% greater compared to healthy volunteers.<br />Hepatic insufficiency: In a study with subjects with varying degrees of hepatic impairment<br />there was no evidence of increased exposure to rosuvastatin in subjects with Child-Pugh scores<br />of 7 or below. However, two subjects with Child-Pugh scores of 8 and 9 showed an increase in<br />systemic exposure of at least 2-fold compared to subjects with lower Child-Pugh scores. There<br />is no experience in subjects with Child-Pugh scores above 9.<br />Genetic polymorphisms: Disposition of HMG-CoA reductase inhibitors, including rosuvastatin,<br />involves OATP1B1 and BCRP transporter proteins. In patients with SLCO1B1 (OATP1B1) and/or<br />ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure.<br />Individual polymorphisms of SLCO1B1 c.521CC and ABCG2 c.421AA are associated with a higher<br />rosuvastatin exposure (AUC) compared to the SLCO1B1 c.521TT or ABCG2 c.421CC genotypes.<br />This specific genotyping is not established in clinical practice, but for patients who are known to<br />have these types of polymorphisms, a lower daily dose of Rosuvastatin is recommended.<br />Pediatric population: Two pharmacokinetic studies with rosuvastatin (given as tablets) in<br />pediatric patients with heterozygous familial hypercholesterolaemia 10-17 or 6-17 years of age<br />(total of 214 patients) demonstrated that exposure in pediatric patients appears comparable to<br />or lower than that in adult patients. Rosuvastatin exposure was predictable with respect to<br />dose and time over a 2-year period.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, genotoxicity and carcinogenicity potential. Specific tests for effects on hERG<br />have not been evaluated. Adverse reactions not observed in clinical studies, but seen in animals<br />at exposure levels similar to clinical exposure levels were as follows: In repeated-dose toxicity<br />studies histopathologic liver changes likely due to the pharmacologic action of rosuvastatin<br />were observed in mouse, rat, and to a lesser extent with effects in the gall bladder in dogs, but<br />not in monkeys. In addition, testicular toxicity was observed in monkeys and dogs at higher<br />dosages. Reproductive toxicity was evident in rats, with reduced litter sizes, litter weight and<br />pup survival observed at maternally toxic doses, where systemic exposures were several times<br />above the therapeutic exposure level.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Crospovidone<br />Tribasic calcium phosphate<br />Lactose Fast Flow<br />Avicel PH 102<br />Magnesium stearate<br />Opadry Pink<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium / Aluminium foil blister<br />Packs of 28 film coated tablets.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical company limited
Jeddah – Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>